In particular, the presence of HLA-DRB1*04 allele in combination with anti–cyclic citrullinated peptide (anti-CCP) antibodies has been associated with development of MTX resistance and it may justify the use of an anti-TNFα agent in patients with early RA [25,102]. This evidence concerns the gene TNF and rheumatoid arthritis.